comprehensive -WSS

comprehensive

author：Wikipedia 2025-08-28 10:50:33 - browse：7688

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： There's an unseen cost to disruptive road

leisure time

WSS

Update the Apgar Score to remove skin color

Rock icon Freddie Mercury pre

Inaction leaves children at risk from dangerous chemotherapy drug

Update the Apgar Score to remove skin color

Lifetime voting ban for felony convictions struck down in Mississippi

High breast density mammograms need follow

hotspot

comprehensive

entertainment

Medicare details structure of new drug price negotiation program

Climate activists disrupt London Pride march to protest corporate sponsorship

Psychedelics group wrestles with new pharma identity

Printout prescription drug information shouldn’t go digital

Hepatitis C has a cure — but many Americans still lack access to it

The inclusion problem at the heart of rehabilitation research

Dobbs anniversary: the lost opportunity of abortion as health care

Medicare bonuses could stop drug shortages under Senate plan

In Memoriam: Notable people who died in 2023

Jesse Tyler Ferguson makes friendship bracelets for Taylor Swift's Eras Tour

focus

Rivals hope for voter 'fatigue' as Trump's woes mount but base stays loyal: ANALYSIS

Special counsel alerts court to Trump’s social media post

New company forms to vet health AI models, root out weaknesses

Inaction leaves children at risk from dangerous chemotherapy drug

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Mass General, Mayo Clinic look to monetize custom

leisure time

explore

leisure time

explore